Institut Jules Bordet — Clinical Trial Site

248 Registered trials

128 Currently recruiting

Organisation

Institut Jules Bordet

Location

Anderlecht, Belgium

Identifier

ORG-100006103

Address

Mijlenmeersstraat 90, 1070, Belgium

Departments

-
#1006: oncology
#2033: Hematology
#2052: Oncologie Médicale
001:Oncologie Médicale
032005:Oncologie Médicale
0501: Clinique d'Oncologie Médicale
0501: Oncologie
0505 Oncologie Médicale
1001:Nucleair Medicine
1108: Hematologie
1602: Hématologie
303: Hematologie
303: Oncologie Médicale
32004: Oncologie Médicale
Chemotherapy
Chirurgie gynécologique
Clinical Hematology
Clinical Trial Conduct Unit
Clinical Trial Conduct Unit (Completed) / Medicine Oncology (Incomplete)
Clinical Trials Conduct Unit
Clinique d'Oncologie Médicale
CTSU ATPT and Medical Oncology
Departement of Hematology
Department of Gastrointestinal Oncology
Department of Haematology
Department of Hematology
Department of Medical Oncology
Department of Oncology
Dept of gastroenterology/hepatopancreatology/digestive oncology
Dept of Medical Oncology
Dept. of Medical Oncology
Digestive Oncology
Gastro-enterology
Gastro-intestinal Medical Oncology
Gastroenterology
GastroIntestinal Medical Oncology
Gynecologic Oncology
Haematology
Hématologie
Hematology
Hematology department
Infectiology
Infectious disease
Infectious diseases
Institut Jules Bordet
Lung Oncology
Medical Oncology
Medical Oncology - GI department
Medical Oncology / Clinical Trials Conduct Unit
Medical oncology department
MEDICAL ONCOLOGY/ HEAD OF CTCU
Medicine Oncology
Medische Oncologie
N/A
NA
Nucleaire geneeskunde
Nuclear medicine
Oncolgy
Oncologie
Oncologie digestive
Oncologie médicale
Oncology
Oncology department
Palliative care
PHU-Digestive Oncology Department
Pneumology
Radiation oncology
Radiotherapy
Radiotherapy-Oncology
Research, Medical oncology
Surgical Oncology
Thoracic Oncology
Thoracic Oncology Clinic
Treatment centre

Clinical trials at this site (248)

Search interface

A Phase 3 Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant Ended

2023-508897-27-00 Multiple Myeloma 5 2022-04-28
Phase 3 study of pembrolizumab vs chemotherapy in dMMR advanced or recurrent endometrial carcinoma Ended

2023-506361-56-00 Endometrial cancer 5 2022-04-01
A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults … Ended

2023-503640-14-00 Newly diagnosed Philadelphia-negative B-cell precursor 5 2022-02-17
A study of lurbinectedin in combination with atezolizumab compared with atezolizumab as maintenance therapy in participants with extensive-s… Ended

2023-503868-16-00 Small-Cell Lung Cancer (SCLC) 5 2022-02-14
A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can… Ended

2023-503826-37-00 Unresectable locally-advanced or metastatic HER2+ breas 5 2022-02-11
Study BT5528-100 in Patients with Advanced Solid Tumors Associated with EphA2 Expression Ended

2024-510655-36-00 Advanced Malignancies Associated with EphA2 Expression 7 2022-02-01
FIRST-IN-HUMAN STUDY OF IPH5301 TREATMENT ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS Ended

2023-504605-36-00 Dose escalation cohort: advanced and/or metastatic canc 1 2022-01-21
OASIS II - A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated ma… Ended

2024-512634-15-00 Patients with untreated mantle cell lymphoma 9 2022-01-05
A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cance… Ended

2023-509133-39-00 Hormone receptor positive, HER2-negative advanced breas 5 2021-11-29
Pembrolizumab/placebo plus paclitaxel with or without bevacizumab for platinum-resistant recurrent ovarian cancer. Ended

2023-506177-35-00 Ovarian, fallopian tube, or primary peritoneal carcinom 11 2021-10-23
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Ended

2023-508838-33-00 Chronic Myeloid Leukemia 5 2021-10-06
EMBER-3 A Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Participants with ER+, HER… Ended

2023-506786-63-00 Breast Cancer 5 2021-09-30
A trial to learn how safe rilvegostomig (AZD2936) is, how it moves throughout the body over time, and how well it works in adults with advan… Ended

2023-508262-15-00 Advanced Non-small Cell Lung Cancer, Metastatic Non-sma 7 2021-09-09
Phase 1 / 2 Study Evaluating MCLA-129 in Advanced NSCLC Ended

2024-514461-19-00 Solid Tumors 9 2021-09-09
DALY 2-EU Ended

2023-506270-13-00 Relapsed/refractory diffuse large B cell lymphoma (R-R 4 2021-07-27
A study to investigate the efficacy and safety of trastuzumab deruxtecan in patients With or Without Brain Metastasis Who Have Previously-Tr… Ended

2024-510588-53-00 Treatment of patients with HER2-positive breast cancer 11 2021-06-10
A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER… Ended

2023-503995-26-00 Estrogen Receptor-Positive, HER2-Negative Advanced Brea 5 2021-05-11
Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended

2023-507961-24-00 High-Risk HER2-Positive Breast Cancer 5 2021-04-19
Phase 3 Study of Belzutifan in Combination With Lenvatinib Versus Cabozantinib for Treatment of RCC Ended

2024-510620-39-00 Advanced RCC with clear cell component 5 2021-04-19
A phase II trial of neoadjuvant REGorafenib in combination with nIvolumab and short-course radiotherapy iN intermediate-risk, stage II-III r… Ended

2024-516554-22-00 Locally-advanced stage II-III rectal cancer 4 2021-03-29
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cance… Ended

2022-502600-79-00 Endometrial cancer 4 2021-03-16
A double-blind study to evaluate the effectiveness and safety of CAEL-101 in patients with AL amyloidosis Ended

2022-503073-11-00 Stage IIIb cardiac AL amyloidosis 5 2021-02-13
KILT - A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERA… Ended

2024-513252-15-00 IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL 4 2021-01-28
A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended

2023-504830-23-00 B-cell Lymphoma 5 2020-12-16